MSF Hits Back At ViiV Over ‘Infuriating’ Cabotegravir Approach

Welcomes MPP Deal For Generics, But Calls For More Transparency From Originator

In the wake of a licensing deal with the MPP that will see three generics firms produce versions of ViiV’s long-acting cabotegravir for lower-income countries, Médecins Sans Frontières has urged the originator to be more transparent about plans to distribute the HIV prevention medicine in high-burden territories.

MSF logo on website through magnifying glass
MSF has criticized ViiV over cabotegravir • Source: Shutterstock

Humanitarian organization Médecins Sans Frontières has urged ViiV Healthcare to provide more transparency over plans to make the firm’s long-acting cabotegravir HIV prevention treatment available in high-burden territories, in the wake of a licensing deal struck by the originator and the Medicines Patent Pool that will see three generics firms produce versions for least developed, low-income, lower-middle-income and sub-Saharan African countries.

Three generics firms – Aurobindo, Cipla and Viatris’s Mylan – recently signed licensing agreements with the MPP that will allow...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Legal & IP

‘Our Position Has Naturally Shifted’ – How Standalone Sandoz Is Taking On Originator Abuses

 
• By 

As a standalone generics and biosimilars company, Sandoz now feels freer to speak out against originator abuses of intellectual property, the firm’s global IP head Julia Pike tells Generics Bulletin, including challenges to Bayer on rivaroxaban and Amgen on etanercept.

MSN’s Entresto Generic Temporarily Blocked As Key US Patent Expires

 
• By 

The Federal Circuit has temporarily blocked MSN from launching a generic version of Entresto, granting Novartis short-term relief while it reviews the company’s emergency Rule 8 motion for a longer injunction.

Room For Improvement? EU Industry Prepares Feedback For SPC Manufacturing Waiver Review

 
• By 

As the European Commission prepares a formal evaluation of the SPC manufacturing waiver, the generics and biosimilars industry is getting ready to provide detailed feedback on what works – and what doesn’t. At Medicines for Europe’s legal affairs conference, delegates heard the latest updates.

The Politics Of Divisionals: How European Patentees Are Still Gaming The System

 
• By 

At Medicines for Europe’s legal affairs conference last month, divisional patents were once again a major subject of discussion. Attendees heard fresh details of how patentee games are preventing generics from hitting the market and restricting wider access to major medicines.

More from Generics Bulletin

Kirsty Gives Biocon A First Interchangeable US Insulin Aspart Biosimilar

 
• By 

After years of waiting, Biocon Biologics has finally snagged US FDA approval for its insulin aspart biosimilar – along with a first designation of interchangeability. However, Sanofi’s Merilog version is already approved as a rival to Novo Nordisk’s Novolog.

MSN’s Entresto Generic Temporarily Blocked As Key US Patent Expires

 
• By 

The Federal Circuit has temporarily blocked MSN from launching a generic version of Entresto, granting Novartis short-term relief while it reviews the company’s emergency Rule 8 motion for a longer injunction.

Making The UK A Leading Biosimilar Launch Destination – Realistic Or Optimistic?

 

Experts discussed the UK government’s commitment to make the country a desirable destination for companies to launch their biosimilars at a recent conference hosted by Medicines UK.